GIPERTROFIK KARDIOMIOPATIYA: KLINIK KUZATUV NATIJALARI VA DAVOGA YONDASHUVLAR
- Авторы:Rasulova Nargis Zafarjonovna. Abdullaev Timur Atanazarovich. Kamolov Nozir Nodirovich. Poʻlatov Xusanjon Ibroxim oʻgʻli
- Дата публикации:September 15, 2025
- Тип:Статья
- DOI: 10.64156/mju.8287 Скопировано
- Том / № Выпуска:Том 1 №4 номер
Аннотация
Annotatsiya. Mazkur maqolada gipertrofik kardiomiyopatiya (GKMP) bilan og‘rigan bemorning klinik kuzatuv natijalari tahlil qilinib, tashxislash algoritmlari va davoga yondashuvlar baholandi. Bemor bo‘yicha ma’lumotlar elektron tarix va rejalashtirilgan nazorat tashriflari asosida yig‘ildi; diagnostika jarayonida elektrokardiografiya, exokardiografiya va laborator tahlil natijalari davriy tahlil qilindi. Dinamik kuzatuvda aritmiyalarni aniqlash va ularni nazorat qilishga alohida e’tibor qaratildi. Ushbu klinik holat GKMP tashxisida yondashuv va davolashni individullashtirish zarurligini, shuningdek, uzoq muddatli monitoring simptomlarni nazorat qilish va asoratlarning oldini olishda muhim ekanini tasdiqlaydi.
Kalit soʻzlar: gipertrofik kardiomiopatiya, sarkomer, proband, boʻlmachalar fibrllyatsiyasi, kardioverter defibrillyator, toʻsatdan koronar oʻlim.
Аннотация. В настоящей статье проанализированы результаты клинического наблюдения за пациенткой с гипертрофической кардиомиопатией (ГКМП), оценены диагностические алгоритмы и подходы к терапии. Клинические данные были собраны на основе электронной истории болезни и плановых визитов; в диагностический процесс входили электрокардиография, эхокардиография и периодический анализ лабораторных показателей. В динамике уделено особое внимание выявлению аритмий и контролю над ними. Представленный клинический случай подтверждает необходимость индивидуализации диагностики и лечения ГКМП, а также демонстрирует значимость длительного мониторинга для контроля симптомов и профилактики осложнений.
Ключевые слова: гипертрофическая кардиомиопатия, саркомер, пробанд, фибрилляция предсердий, кардиовертер-дефибриллятор, внезапная сердечная смерть.
Abstract. This article analyzes the clinical follow-up results of a patient with hypertrophic cardiomyopathy (HCM) and evaluates diagnostic algorithms and therapeutic approaches. Patient data were collected from the electronic medical record and scheduled follow-up visits; the diagnostic work-up included electrocardiography, echocardiography, and periodic laboratory assessments. Particular attention during longitudinal observation was given to detecting and controlling arrhythmias. This clinical case underscores the need for individualized diagnostic and treatment strategies in HCM and highlights the importance of long-term monitoring to control symptoms and prevent complications.
Keywords: hypertrophic cardiomyopathy, sarcomere, proband, atrial fibrillation, cardioverter-defibrillator, sudden cardiac death.
References
- 1. Бокерия, Л. А., Шляхто, Е. В., Габрусенко, С. А., Гудкова, А. Я., Козиолова, Н.., Александрова, С. А., Алехин, М. Н., Афанасьев, А. В., Богатырева, М. М., Богачев-Прокофьев, А. В., Богданов, Д. В., Берсенева, М. И., Гордеев, М. Л., Дзeмешкевич, С. Л., Евтушенко, А. В., Заклязьминская, Е. В., Зенченко, Д. И., Иртюга, О. Б., Каплунова, В. Ю., Каштанов, М. Г., … Шлойдо, Е. А. (2025). Гипертрофическая кардиомиопатия. Клинические рекомендации 2025. Российский кардиологический журнал, 30(5), 6387. https://doi.org/10.15829/1560-4071-2025-6387
- 2. Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., Bryant, W. J., Callans, D. J., Curtis, A. B., ... & Page, R. L. (2018). 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm, 15(10), e73–e189. https://doi.org/10.1016/j.hrthm.2017.10.036
- 3. Arbustini, E., Narula, N., Dec, G. W., Reddy, K. S., Greenberg, B., Kushwaha, S., ... & Narula, J. (2023). 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal, 44(40), 3644–3726. https://doi.org/10.1093/eurheartj/ehad194
- 4. Braunwald, E., Saberi, S., Abraham, T. P., Elliott, P. M., & Olivotto, I. (2023). Mavacamten: A first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. European Heart Journal, 44(44), 4622–4633.
- 5. Burke, M. A., Cook, S. A., Seidman, J. G., et al. (2016). Clinical and mechanistic insights into the genetics of cardiomyopathy. Journal of the American College of Cardiology, 68, 2871–2886.
- 6. Capota, R., Militaru, S., Ionescu, A. A., Rosca, M., Baicus, C., Popescu, B. A., et al. (2020). Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire. Health and Quality of Life Outcomes, 18, 1–8.
- 7. Cleland, J. G. F., Daubert, J. C., Erdmann, E., Freemantle, N., Gras, D., Kappenberger, L., & Tavazzi, L. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine, 352(15), 1539–1549. https://doi.org/10.1056/NEJMoa050496
- 8. Desai, A. S., Owens, A. T., Shah, P. B., Cremer, P. C., Friedman, A., Bahrami, H., ... & Rowin, E. J. (2022). Mavacamten in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy (VALOR-HCM). Circulation, 146(10), 740–754. https://doi.org/10.1161/CIRCULATIONAHA.122.060570
- 9. Dong, T., Alencherry, B., Ospina, S., & Desai, M. Y. (2023). Review of mavacamten for obstructive hypertrophic cardiomyopathy and future directions. Drug Design, Development and Therapy, 17, 1097–1106.
- 10. Dybro, A. M., Rasmussen, T. B., Nielsen, R. R., Andersen, M. J., Jensen, M. K., & Poulsen, S. H. (2021). Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 78, 2505–2517.
- 11. Eberly, L. A., Day, S. M., Ashley, E. A., et al. (2020). Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiology, 5, 83–91.
- Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., ... & Watkins, H. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 35(39), 2733–2779. https://doi.org/10.1093/eurheartj/ehu284
- 13. Firoozi, S., Elliott, P. M., Sharma, S., et al. (2002). Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: A comparison of clinical, haemodynamic and exercise outcomes. European Heart Journal, 23, 1617–1624. https://doi.org/10.1053/euhj.2002.3285
- 14. Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., ... & Yancy, C. W. (2011). 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 58(25), e212–e260. https://doi.org/10.1016/j.jacc.2011.06.011
- 15. Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895–e1032.
- 16. Ho, C. Y., Day, S. M., Ashley, E. A., et al. (2018). Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRE). Circulation, 138, 1387–1398.